ARROWSTREET CAPITAL, LIMITED PARTNERSHIP
Position in NUVB — Nuvation Bio Inc.
CIK 1164508
BOSTON, MA
Position in NUVB
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$6,174,841
-$1,169,061 QoQ
Shares Held
1,439,357
+75.6% QoQ
Ownership
0.413%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2024
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NUVB Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026ARROWSTREET CAPITAL, LIMITED PARTNERSHIP holds $1,767,735,657 across 48 Biotechnology names. NUVB ranks #29 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
638,950 | $285,316,733 | |
| 2 | INCY |
Incyte Corp
|
2,830,799 | $266,434,801 | |
| 3 | EXEL |
Exelixis, Inc.
|
4,834,625 | $207,357,066 | |
| 4 | GMAB |
Genmab A/S
|
4,975,324 | $133,487,942 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
171,571 | $132,562,617 | |
| 6 | HALO |
Halozyme Therapeutics, Inc.
|
1,918,149 | $123,969,969 | |
| 7 | RPRX |
Royalty Pharma plc
|
2,010,398 | $96,438,792 | |
| 8 | IONS |
Ionis Pharmaceuticals Inc
|
737,859 | $55,405,832 |
All Filings in NUVB
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $6,174,841 | 1,439,357 | Shares | Defined | 2026-05-14 | |
| 2025-12-31 | $7,343,902 | 819,632 | Shares | Defined | 2026-02-13 | |
| 2025-09-30 | $1,716,785 | 463,996 | Shares | Defined | 2025-11-13 | |
| 2024-03-31 | $139,244 | 38,254 | Shares | Defined | 2024-05-15 | |
| No filing history on record for this holder in this stock. | ||||||